Abstract
The drug discovery market based on RNAi is projected to be $650 million in 2005 and $1 billion by 2010. Dont miss out on your share of this growing market! The increasing demand for target validation and the large number of new potential targets has augmented the need and importance of RNAi in sorting through the possibilities. The future is bright for this technology in that it may supplant or complement crucial existing technologies such as antisense and knockout models. As the first drugs are commercialized there will be an even greater interest in this exciting new technology.
Table of Contents
1 Executive Summary
2 Small Interfering RNAs
- Background of small interfering RNAs
- Current Frontier of Research in RNAi
3 Market Drivers
- Cost of drug development
- Diseases ideal for siRNA therapeutics
4 Other RNAi Technology in Target Validation and Therapeutics
- Antisense
- Ribozyme
- Aptamers
- Peptide Nucleic Acids
- Morpholinos
5 Other Rival Technologies in Target Validation
- Gene knockouts
6 Related Technologies Critical to High Throughput Target Validation
- Protein profiling technology
- Phenotype profiling technology
7 Company Profiles
- Profiles of companies developing siRNA therapeutics
- Profiles of companies developing siRNA mediated target validation
- Profiles of companies supplying siRNA related reagents
8 Trends
- Strengths
- Weaknesses
- Opportunities
